Baxter International Inc. has trimmed its 2025 financial outlook due to disappointing quarterly earnings and the lingering effects of Hurricane Helene, leading to a decline in its stock price.

Baxter International Inc. has trimmed its 2025 financial outlook due to challenges from Hurricane Helene, which damaged a key manufacturing facility and disrupted its supply chain.

Baxter International Inc. is poised to capitalize on the growing biosurgery and hemostats markets, projected to reach $21.59 billion and $4.25 billion by 2030 and 2031, respectively.

Baxter International Inc. has boosted its fiscal year 2025 outlook after a strong Q1 performance, exceeding earnings estimates and prompting a positive market reaction.

Baxter International Inc. is at a critical juncture as it prepares to release its Q1 earnings, with investors eagerly awaiting signs of growth and stability amidst a volatile market and intense industry competition.